Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Why CELMoDs Matter in Myeloma
Sagar Lonial, MD, FACP
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Noopur Raje, MD
Data Dive: Clinical Evidence Behind CELMoDs
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Safety First: Navigating CELMoD-Associated Toxicities
Joshua Richter, MD
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Insights and Updates: New Data on Next-Generation Retinal Treatments
Durga Borkar, MD, MMCi
Veeral Sheth, MD, MBA, FASRS, FACS
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Real-World Ready: Practical Tips for Community Oncologists
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Maria Fleseriu, MD, FACE
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Hussein Tawbi, MD, PhD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Mastering the Sequence: CELMoDs Across Treatment Lines
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.